Search
인용 및 참조 문헌 (1)
Invitrogen™
LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting, with GFP
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control자세히 알아보기
Have Questions?
보기 방식 변경
| 카탈로그 번호 | 수량 |
|---|---|
| A32063 | 100 μL |
| A32831 | 1 mL |
카탈로그 번호 A32063
제품 가격(KRW)
726,000
Online offer
Ends: 31-Dec-2025
806,000할인액 80,000 (10%)
Each
수량:
100 μL
제품 가격(KRW)
726,000
Online offer
Ends: 31-Dec-2025
806,000할인액 80,000 (10%)
Each
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control Lentivirus, Human Scrambled, contains a gRNA sequence with no sequence homology to any region of the human genome. This construct also expresses emGFP to provide a visual readout of successful transduction that can be used in determining Multiplicity of Infection (MOI).
For Research Use Only. Not for use in diagnostic procedures.
사양
배달 유형Lentiviral
용도(애플리케이션)Genome Editing
제품라인LentiArray
제품 유형gRNA
프로모터U6
수량100 μL
배송 조건Dry Ice
제어 유형Negative Control
형식Tube
RNAi TypegRNA
종Human
Unit SizeEach
구성 및 보관
1 x 100 μL. Store (at -68°C to -85°C.)
인용 및 참조 문헌 (1)
인용 및 참조 문헌
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific